temozolomide has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 9 studies
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ)." | 7.76 | Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. ( Hosono, A; Makimoto, A; Miyakita, Y; Momota, H; Nariata, Y; Narita, Y; Shibui, S, 2010) |
| "However, TMZ-related acute lymphoblastic leukemia is rare." | 5.40 | Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient. ( Chang, PY; Chou, KN; Lin, YC; Liu, MY, 2014) |
| "Twenty patients (16 with acute myelogenous leukemia, two with acute lymphoblastic leukemia, and two with chronic myelogenous leukemia in blastic phase) received 43 cycles of temozolomide." | 5.10 | Phase I study of temozolomide in relapsed/refractory acute leukemia. ( Ahmed, T; Baskind, P; Liu, D; Loughran, T; Seiter, K; Siddiqui, A, 2002) |
| "We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ)." | 3.76 | Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. ( Hosono, A; Makimoto, A; Miyakita, Y; Momota, H; Nariata, Y; Narita, Y; Shibui, S, 2010) |
| "However, TMZ-related acute lymphoblastic leukemia is rare." | 1.40 | Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient. ( Chang, PY; Chou, KN; Lin, YC; Liu, MY, 2014) |
| "Cotreatment with methoxyamine, a base excision repair inhibitor, did not sensitize CEM-R cells to TMZ, suggesting little or no contribution of N-alkylation to TMZ-induced cytotoxicity." | 1.35 | Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance. ( Ogawa, M; Ueda, T; Yamauchi, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, KN | 1 |
| Lin, YC | 1 |
| Liu, MY | 1 |
| Chang, PY | 1 |
| Seiter, K | 2 |
| Katragadda, S | 1 |
| Ponce, D | 1 |
| Rasul, M | 1 |
| Ahmed, N | 1 |
| Momota, H | 1 |
| Narita, Y | 1 |
| Nariata, Y | 1 |
| Miyakita, Y | 1 |
| Hosono, A | 1 |
| Makimoto, A | 1 |
| Shibui, S | 1 |
| Ogura, M | 1 |
| Todo, T | 1 |
| Tanaka, M | 1 |
| Nannya, Y | 1 |
| Ichikawa, M | 1 |
| Nakamura, F | 1 |
| Kurokawa, M | 1 |
| Brown, CC | 1 |
| Havener, TM | 1 |
| Medina, MW | 1 |
| Auman, JT | 1 |
| Mangravite, LM | 1 |
| Krauss, RM | 1 |
| McLeod, HL | 1 |
| Motsinger-Reif, AA | 1 |
| Liu, D | 1 |
| Loughran, T | 1 |
| Siddiqui, A | 1 |
| Baskind, P | 1 |
| Ahmed, T | 1 |
| Hargrave, D | 1 |
| Bouffet, E | 1 |
| Gammon, J | 1 |
| Becker, L | 1 |
| Rutka, J | 1 |
| Baruchel, S | 1 |
| Yamauchi, T | 1 |
| Ogawa, M | 1 |
| Ueda, T | 1 |
| Deans, B | 1 |
| Tisdale, MJ | 1 |
1 review available for temozolomide and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Temozolomide may induce therapy-related acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Neoplasms, Second Primary; Precursor | 2011 |
2 trials available for temozolomide and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Temozolomide and cisplatin in relapsed/refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Resistance | 2009 |
Phase I study of temozolomide in relapsed/refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug | 2002 |
6 other studies available for temozolomide and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Cytogenetic Analysis; Dacarbazine; | 2014 |
Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazine; Female; Frontal | 2010 |
A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification | 2012 |
Response to low dose temozolomide in radiation induced gliomatosis cerebri.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Leukemi | 2003 |
Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadmiu | 2008 |
Antitumour imidazotetrazines XXVIII 3-methyladenine DNA glycosylase activity in cell lines sensitive and resistant to temozolomide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Burkitt Lymphoma; Cell Line; Cell Survival; Chromato | 1992 |